Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Program Title

Understanding the Complexities of Cardiovascular Comorbidities
Release Date: March-31-05
Credit Expiration Date: March-31-06

Faculty

Shari R. Fine, DO, FACOFP
Director, FP Residency Program
University of Medicine and Dentistry
of New Jersey
Jersey City, NJ

David A. Garcia, MD
University of New Mexico School of Medicine
Albuquerque, NM

Pamela R. Kushner, MD
Associate Clinical Professor
University of California at Irvine
College of Medicine
Irvine, CA

L. Michael Prisant, MD, FACC, FACP
Professor of Medicine
Director, Hypertension and Clinical Pharmacology
Medical College of Georgia
Augusta, GA

William A. Schwer, MD
Chairman, Department of Family Medicine
Rush-Presbyterian-St. Luke's Medical Center
Chicago, IL

Credit Hours

Physicians & PAs: 1
Nurses & NPs: 1.2

Medium

Online Presentation

Program Description

Management of patients with CV comorbidities such as hypertension, diabetes and heart failure is complex, demanding and integrative, and aggressive measures are needed to avert outcomes like myocardial infarction, atrial fibrillation and stroke, and related early mortality. To assist the clinician in the management of patients with cardiovascular comorbidities, the faculty in this program knitted together findings from the latest studies and current clinical guidelines to achieve optimal risk reduction in the growing number of high-risk CV patients with multiple comorbidities.

The content of this activity has been excerpted from a roundtable discussion held in Orlando, Florida on October 15th, 2004. The original program was jointly sponsored by the University of Wisconsin Medical School and ProCom.

Program Developer/Facilitator


.

Target Audience

This activity has been designed for physicians, physician assistants, nurses and nurse practitioners interested in the care of patients with cardiovascular disease and related comorbidities.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Discuss the current understanding of cardiovascular disease in relation to a synergy of risk factors, hypertension, hyperlipidemia, and Type II diabetes.
  2. Describe the importance of early identification of Type II diabetes and comprehensive treatment of comorbid conditions.
  3. Cite data and recommendations regarding blood pressure goals and pharmacologic and nonpharmacologic approaches to achieving these goals.
  4. Develop strategies to apply current cholesterol guidelines, with particular attention to LDL-C, to clinical practice.
  5. Discuss emerging clinical evidence regarding the use of antithrombotic therapy in patients with atrial fibrillation.

Disclosures

It is the policy of AKH Inc. that the faculty disclose real or apparent conflicts of interest relating to the topic of this CME/CE activity, and also disclose discussions of unlabeled /unapproved uses of drugs or devices during their presentations. The faculty has disclosed the following:

Dr. Schwer: No potential conflicts of interest.

Dr. Prisant: Grants/research supported by: Abbott Laboratories; AstraZeneca; Boehringer Ingelheim Corporation; Bristol-Myers Squibb; Forest Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Sankyo Pharma; Schwarz Pharma. Consultant for: Abbott Laboratories; AstraZeneca; Boehringer Ingelheim Corporation; Bristol-Myers Squibb; Forest Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Sankyo Pharma; Schwarz Pharma. Honoraria supported by: Abbott Laboratories; AstraZeneca; Boehringer Ingelheim Corporation; Bristol-Myers Squibb; Forest Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Sankyo Pharma; Schwarz Pharma.

Dr. Kushner: Grants/research supported by AstraZeneca. Consultant for: AstraZeneca.

Dr. Fine: No potential conflicts of interest.

Dr. Garcia: Grants/research supported by: Sanofi-Aventis, AstraZeneca. Consultant for: Sanofi-Aventis, AstraZeneca.
Honoraria supported by: Sanofi-Aventis, AstraZeneca.

This course is meant to educate healthcare professionals regarding currently approved treatments and those that may be available in the future, off-label use will be discussed.

Credit Statements

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc. designates this educational activity for a maximum of 1 category 1 credit towards the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

This educational activity for 1.2 contact hours (0.12 CEU) is provided by AKH Inc. AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.2 contact hours (0.12 CEU) is provided by AKH Inc. which. is approved as a provider of nursing and nurse practitioner continuing education by the American Academy of Nurse Practitioners, #030803.

This program has been reviewed and is approved for a maximum of 1 hour of professional Category 1 (Preapproved) CME credit by the American Academy of Physician Assistants. Approval is valid for 1 year from the issue date of March 31, 2005. Participants may submit the self-assessment at any time during that period.

This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

Commercial Support Statements

This program was made possible through an educational grant from
AstraZeneca.

Instructions

  1. Upon completion of the program, click on the post-test button to access the post-test and program evaluation. You will be asked to select from separate post-tests for physicians, physician assistants, nurses, and nurse practitioners. Physicians, nurses and nurse practitioners must be registered with cmecorner.com in order to complete the post-test. When physicians, nurses and NPs click on the post-test button they will be brought to a screen which will confirm their registration status and provide an opportunity to register if they haven't done so previously.
  2. Clicking on "start the program" on this screen will begin the program presentation which will take approximately 60 minutes to complete.
  3. Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CE certificate which will be mailed 4-6 weeks after submission.
  4. Click on the "Start program" icon.
  5. The next screen will permit you to check for or download the Flash player required to run this program.

Certificate Fee

$0.00

Physician assistants who are not members of the AAPA are required to pay a $20 scoring fee. There is no charge for physicians, AAPA members, nurses, or NPs.

Disclaimer

The information contained in this program does not necessarily reflect the opinions or recommendations of AKH, Inc., AstraZeneca, or Medical Communications Media, Inc. Diagnostic procedures or treatments discussed in the program should not be utilized by clinicians without evaluation of patients’ conditions and possible contraindications or risks, and without a review of applicable manufacturer’s product information and comparison with recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS